Our Ophthalmic Clinical Development News Archive | Ora

For the latest updates on how we are managing changes due to COVID-19 please click here.

Ora®, Inc. has been retained by ProQR Therapeutics to provide mobility test services using the Ora-VNC™ for the QR-110 development program for Leber’s Congenital Amaurosis Type 10

News November, 2018

Will the Evolving Economic Landscape for Dry Eye Products Impact Investment?

Articles October, 2018

Keith Lane Discussing Ora’s Standardized Mobility Course (Ora-VNC™)

Articles October, 2018

Presbyopia Therapies Announces Primary Safety and Efficacy Endpoints met in a Phase IIb study of its Topical PRX Ophthalmic Solution for the Treatment of Presbyopia

Articles June, 2018

Ora, Inc. Unifies its Clinical Environment with Veeva to Accelerate Trial Execution

News March, 2018

TopiVert demonstrates proof of concept in Phase 1/2a study of TOP1630 in the treatment of dry eye syndrome

News November, 2017

Veeva Vault CTMS Gains Momentum as Industry Moves to Unify Clinical Applications and Processes

Articles June, 2017

CTMS cloud application streamlines trial management and delivers end-to-end visibility of clinical trials on one platform

Ora presented 16 posters at this year’s ARVO

Articles May, 2017

Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production

Articles April, 2017

AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications

Articles March, 2017

« 1 2 3 … 7 »